Evidence map›Paper›PMID 33643904›Full record

ArticleFrontiers in oncology2020

Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature.

Cheng-Sheng Liu, Jia-Ruey Tsai, Yi-Tzu Kao, Long-Sheng Lu, Yin-Ju Chen, Thierry Burnouf, Peng-Yuan Wang, Jeng-Fong Chiou, Lai-Lei Ting

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Cheng-Sheng LiuDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Jia-Ruey TsaiDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Yi-Tzu KaoDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Long-Sheng LuDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Yin-Ju ChenDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Thierry BurnoufGraduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
Peng-Yuan WangCentre for Human Tissue & Organs Degeneration, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Jeng-Fong ChiouDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Lai-Lei TingDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Taipei Medical University Hospital · TWTaipei Medical University · TWSwinburne University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular leiomyosarcoma is an extremely rare tumor and is associated with poor prognosis among leiomyosarcoma. Surgical resection remains the main treatment option. But outcome of definitive treatment with chemoradiotherapy in inoperable patients is not clear. Here, we report treatment and outcome of definitive chemoradiotherapy in a case of vascular leiomyosarcoma. A 64-year-old man with the initial presentation of pulsatile right neck mass was diagnosed with right carotid body leiomyosarcoma. He refused surgical intervention due to risk of carotid body injury and ischemic stroke. Successful tumor control was achieved with carboplatin-based concurrent chemoradiotherapy. Investigational liquid biopsy for circulating sarcoma cells was also performed to analyze drug sensitivity profile of this rare tumor. One year after treatment, the disease remained well controlled and there was no evidence of baroreflex failure or treatment-related late toxicities. To our best knowledge, this is the first case report of right carotid body leiomyosarcoma controlled with definitive concurrent chemoradiotherapy. The approach of personalized multi-modality treatment will be a focus of our future investigation.

Indexed as

carotid body tumorcase reportconcurrent chemoradiotherapyleiomyosarcomaliquid biopsy

Identifiers

PMID33643904
PMCPMC7906006
OpenAlexW3132518718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.